MDMA exposure alters cognitive and electrophysiological sensitivity to rapid tryptophan depletion in rhesus monkeys

Pharmacology Biochemistry and Behavior

Volumn 76, Issue 1, 2003, Pages 141-152

  Taffe, Michael A ^a   Huitrón Resendiz, Salvador ^a   Schroeder, Richard ^a   Parsons, Loren H ^a   Henriksen, Steven J ^a   Gold, Lisa H ^a,b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b PFIZER INC   (United States)

Author keywords

CANTAB; Ecstasy; Evoked potential; Memory; Tryptophan

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5 HYDROXYINDOLEACETIC ACID; AMINO ACID; SEROTONIN; TRYPTOPHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; BRAIN FUNCTION; BRAIN STEM; CEREBROSPINAL FLUID LEVEL; CHEMOSENSITIVITY; COGNITION; CONTROLLED STUDY; DEPLETION; ELECTROPHYSIOLOGY; EVOKED AUDITORY RESPONSE; EXPOSURE; LATENT PERIOD; MENTAL PERFORMANCE; MOTOR CONTROL; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; REACTION TIME; REINFORCEMENT; RHESUS MONKEY; SIGNAL TRANSDUCTION; SPATIAL MEMORY; VISUAL MEMORY; WORKING MEMORY;

ANIMALS; BRAIN; COGNITION; ELECTROPHYSIOLOGY; EVOKED POTENTIALS, AUDITORY; MACACA MULATTA; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS; REACTION TIME; TRYPTOPHAN;

CERCOPITHECIDAE; MACACA; MACACA MULATTA;

EID: 1642284491     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(03)00217-X     Document Type: Article

References (75)

1. Ballenger J.C., Goodwin F.K., Major L.F., Brown G.L. Alcohol and central serotonin metabolism in man. Arch. Gen. Psychiatry. 36:1979;224-227.
2. Bhattachary S., Powell J.H. Recreational use of 3,4- methylenedioxymethamphetamine (MDMA) or 'ecstasy': evidence for cognitive impairment. Psychol. Med. 31:2001;647-658.
3. Carpenter L.L., Anderson G.M., Pelton G.H., Gudin J.A., Kirwin P.D., Price L.H.et al. Tryptophan depletion during continuous CSF sampling in healthy human subjects. Neuropsychopharmacology. 19:1998;26-35.
4. Chamberlain B., Ervin F.R., Pihl R.O., Young S.N. The effect of raising or lowering tryptophan levels on aggression in vervet monkeys. Pharmacol. Biochem. Behav. 28:1987;503-510.
5. Chotai J., Adolfsson R. Converging evidence suggests that monoamine neurotransmitter turnover in human adults is associated with their season of birth. Eur. Arch. Psychiatry Clin. Neurosci. 252:2002;130-134.
6. Clark J.D., Baldwin R.L., Bayne K.A., Brown M.J., Gebhart G.F., Gonder J.C.et al. Guide for the care and use of laboratory animals. 1996;Institute of Laboratory Animal Resources, National Research Council, Washington (DC).
7. Coull J.T., Sahakian B.J., Middleton H.C., Young A.H., Park S.B., McShane R.H.et al. Differential effects of clonidine, haloperidol, diazepam and tryptophan depletion on focused attention and attentional search. Psychopharmacology (Berl.). 121:1995;222-230.
8. Croft R.J., Mackay A.J., Mills A.T., Gruzelier J.G. The relative contributions of ecstasy and cannabis to cognitive impairment. Psychopharmacology (Berl.). 153:2001;373-379.
9. Fairbanks L.A., Melega W.P., Jorgensen M.J., Kaplan J.R., McGuire M.T. Social impulsivity inversely associated with CSF 5-HIAA and fluoxetine exposure in vervet monkeys. Neuropsychopharmacology. 24:2001;370-378.
10. Fils-Aime M.L., Eckardt M.J., George D.T., Brown G.L., Mefford I., Linnoila M. Early-onset alcoholics have lower cerebrospinal fluid 5-hydroxyindoleacetic acid levels than late-onset alcoholics. Arch. Gen. Psychiatry. 53:1996;211-216.
11. Fray P.J., Sahakian B.J., Robbins T.W., Koob G.F., Iversen S.D. An observational method for quantifying the behavioural effects of dopamine agonists: contrasting effects of d-amphetamine and apomorphine. Psychopharmacology (Berl.). 69:1980;253-259.
12. Frederick D.L., Ali S.F., Slikker W. Jr., Gillam M.P., Allen R.R., Paule M.G. Behavioral and neurochemical effects of chronic methylenedioxymethamphetamine (MDMA) treatment in rhesus monkeys. Neurotoxicol. Teratol. 17:1995;531-543.
13. Frederick D.L., Ali S.F., Gillam M.P., Gossett J., Slikker W., Paule M.G. Acute effects of dexfenfluramine (d-FEN) and methylenedioxymethamphetamine (MDMA) before and after short-course, high-dose treatment. Ann. N. Y. Acad. Sci. 844:1998;183-190.
14. George D.T., Umhau J.C., Phillips M.J., Emmela D., Ragan P.W., Shoaf S.E.et al. Serotonin, testosterone and alcohol in the etiology of domestic violence. Psychiatry Res. 104:2001;27-37.
15. Glantz S.A. Primer of biostatistics. 5th ed. 2002;McGraw-Hill, New York.
16. Gouzoulis-Mayfrank E., Daumann J., Tuchtenhagen F., Pelz S., Becker S., Kunert H.J.et al. Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J. Neurol. Neurosurg. Psychiatry. 68:2000;719-725.
17. Harrison A.A., Everitt B.J., Robbins T.W. Central 5-HT depletion enhances impulsive responding without affecting the accuracy of attentional performance: interactions with dopaminergic mechanisms. Psychopharmacology (Berl.). 133:1997;329-342.
18. Higley J.D., Mehlman P.T., Poland R.E., Taub D.M., Vickers J., Suomi S.J.et al. CSF testosterone and 5-HIAA correlate with different types of aggressive behaviors. Biol. Psychiatry. 40:1996;1067-1082.
19. Johnston L.D., O'Malley P.M., Bachman J.G. Ecstasy use among American teens drops for the first time in recent years, and overall drug and alcohol use also declines in the year after 9/11. http://www.monitoringthefuture.org: 2002.
20. Johnston L.D., O'Malley P.M., Bachman J.G. Monitoring the future national survey results on drug use, 1975-2001. Secondary school students. vol. I:2002;503 National Institute on Drug Abuse, Bethesda (MD).
21. Johnston L.D., O'Malley P.M., Bachman J.G. Monitoring the Future national survey results on drug use, 1975-2001. College students and adults ages 19-40. vol. II:2002;242 National Institute on Drug Abuse, Bethesda (MD).
22. Kaye W.H., Greeno C.G., Moss H., Fernstrom J., Fernstrom M., Lilenfeld L.R.et al. Alterations in serotonin activity and psychiatric symptoms after recovery from bulimia nervosa. Arch. Gen. Psychiatry. 55:1998;927-935.
23. Kullback S. Information theory and statistics. 2nd ed. 1968;Dover Publications Inc. New York.
24. LeMarquand D.G., Benkelfat C., Pihl R.O., Palmour R.M., Young S.N. Behavioral disinhibition induced by tryptophan depletion in nonalcoholic young men with multigenerational family histories of paternal alcoholism. Am. J. Psychiatry. 156:1999;1771-1779.
25. Luciana M., Burgund E.D., Berman M., Hanson K.L. Effects of tryptophan loading on verbal, spatial and affective working memory functions in healthy adults. J. Psychopharmacol. 15:2001;219-230.
26. Mann J.J., Arango V. Integration of neurobiology and psychopathology in a unified model of suicidal behavior. J. Clin. Psychopharmacol. 12:1992;2S-7S.
27. McCann U.D., Szabo Z., Scheffel U., Dannals R.F., Ricaurte G.A. Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human being [see comments]. Lancet. 352:1998;1433-1437.
28. McCann U.D., Mertl M., Eligulashvili V., Ricaurte G.A. Cognitive performance in (+/-) 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users: a controlled study. Psychopharmacology (Berl.). 143:1999;417-425.
29. McKenna D.J., Peroutka S.J. Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). J. Neurochem. 54:1990;14-22.
30. Mobini S., Chiang T.J., Ho M.Y., Bradshaw C.M., Szabadi E. Effects of central 5-hydroxytryptamine depletion on sensitivity to delayed and probabilistic reinforcement. Psychopharmacology (Berl.). 152:2000;390-397.
31. Moeller F.G., Dougherty D.M., Swann A.C., Collins D., Davis C.M., Cherek D.R. Tryptophan depletion and aggressive responding in healthy males. Psychopharmacology (Berl.). 126:1996;97-103.
32. Moore P., Landolt H.P., Seifritz E., Clark C., Bhatti T., Kelsoe J.et al. Clinical and physiological consequences of rapid tryptophan depletion. Neuropsychopharmacology. 23:2000;601-622.
33. Morgan M.J. Memory deficits associated with recreational use of "ecstasy" (MDMA). Psychopharmacology (Berl.). 141:1999;30-36.
34. Motulsky H. Intuitive biostatistics. 1995;Oxford Univ. Press, New York.
35. Nishizawa S., Benkelfat C., Young S.N., Leyton M., Mzengeza S., de Montigny C.et al. Differences between males and females in rates of serotonin synthesis in human brain. Proc. Natl. Acad. Sci. U. S. A. 94:1997;5308-5313.
36. Palmour R.M., Ervin F.R., Baker G.B., Young S.N. An amino acid mixture deficient in phenylalanine and tyrosine reduces cerebrospinal fluid catecholamine metabolites and alcohol consumption in vervet monkeys. Psychopharmacology (Berl.). 136:1998;1-7.
37. Park S.B., Coull J.T., McShane R.H., Young A.H., Sahakian B.J., Robbins T.W.et al. Tryptophan depletion in normal volunteers produces selective impairments in learning and memory. Neuropharmacology. 33:1994;575-588.
38. Peroutka S.J. Incidence of recreational use of 3,4- methylenedimethoxymethamphetamine (MDMA, "ecstasy") on an undergraduate campus. [letter] N. Engl. J. Med. 317:1987;1542-1543.
39. Pietraszek M.H., Urano T., Sumioshi K., Serizawa K., Takahashi S., Takada Y.et al. Alcohol-induced depression: involvement of serotonin. Alcohol Alcohol. 26:1991;155-159.
40. Pope H.G. Jr., Ionescu-Pioggia M., Pope K.W. Drug use and life style among college undergraduates: a 30-year longitudinal study. Am. J. Psychiatry. 158:2001;1519-1521.
41. Prell G.D., Khandelwal J.K., Burns R.S., Green J.P. Histamine metabolites in cerebrospinal fluid of the rhesus monkey (Macaca mulatta): cisternal-lumbar concentration gradients. J. Neurochem. 50:1988;1194-1199.
42. Reneman L., Booij J., Schmand B., van den Brink W., Gunning B. Memory disturbances in ("Ecstasy") users are correlated with an altered brain serotonin neurotransmission. Psychopharmacology (Berl.). 148:2000;322-324.
43. Reneman L., Lavalaye J., Schmand B., de Wolff F.A., van den Brink W., den Heeten G.J.et al. Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"): preliminary findings. Arch. Gen. Psychiatry. 58:2001;901-906.
44. Ricaurte G.A., DeLanney L.E., Wiener S.G., Irwin I., Langston J.W. 5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in CNS of non-human primates. Brain Res. 474:1988;359-363.
45. Ricaurte G.A., Yuan J., McCann U.D. (+/-)3,4- Methylenedioxymethamphetamine ('ecstasy')-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology. 42:2000;5-10.
46. Riedel W.J., Klaassen T., Deutz N.E., van Someren A., van Praag H.M. Tryptophan depletion in normal volunteers produces selective impairment in memory consolidation. Psychopharmacology (Berl.). 141:1999;362-369.
47. Robbins T.W. A critique of the methods available for the measurement of spontaneous motor activity. Snyder S.H. Handbook of psychopharmacology. 1977;Plenum, New York.
48. Rodgers J. Cognitive performance amongst recreational users of "ecstasy" Psychopharmacology (Berl.). 151:2000;19-24.
49. Rubinsztein J.S., Rogers R.D., Riedel W.J., Mehta M.A., Robbins T.W., Sahakian B.J. Acute dietary tryptophan depletion impairs maintenance of "affective set" and delayed visual recognition in healthy volunteers. Psychopharmacology (Berl.). 154:2001;319-326.
50. Ruckebusch M., Sutra J.F. On the significance of monoamines and their metabolites in the cerebrospinal fluid of the sheep. J. Physiol. 348:1984;457-469.
51. Sahgal A., Petrides M., Iversen S.D. Cross-modal matching in the monkey after discrete temporal lobe lesions. Nature. 257:1975;672-674.
52. Schmitt J.A., Jorissen B.L., Sobczak S., van Boxtel M.P., Hogervorst E., Deutz N.E.et al. Tryptophan depletion impairs memory consolidation but improves focused attention in healthy young volunteers. J. Psychopharmacol. 14:2000;21-29.
53. Schuster P., Lieb R., Lamertz C., Wittchen H.U. Is the use of ecstasy and hallucinogens increasing? Results from a community study. Eur. Addict. Res. 4:1998;75-82.
54. Schwartz P.J., Murphy D.L., Wehr T.A., Garcia-Borreguero D., Oren D.A., Moul D.E.et al. Effects of meta-chlorophenylpiperazine infusions in patients with seasonal affective disorder and healthy control subjects. Diurnal responses and nocturnal regulatory mechanisms. Arch. Gen. Psychiatry. 54:1997;375-385.
55. Semple D.M., Ebmeier K.P., Glabus M.F., O'Carroll R.E., Johnstone E.C. Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ("ecstasy") users. Br. J. Psychiatry. 175:1999;63-69.
56. Soderpalm B., Svensson A.I. Naloxone reverses disinhibitory/aggressive behavior in 5,7-DHT-lesioned rats; involvement of GABA(A) receptor blockade? Neuropharmacology. 38:1999;1851-1859.
57. Steele T.D., McCann U.D., Ricaurte G.A. 3,4- Methylenedioxymethamphetamine (MDMA, "ecstasy"): pharmacology and toxicology in animals and humans. Addiction. 89:1994;539-551.
58. Taffe M.A., Weed M.R., Gold L.H. Scopolamine alters rhesus monkey performance on a novel neuropsychological testing battery. Cog. Br. Res. 8:1999;203-212.
59. Taffe M.A., Weed M.R., Davis S., Huitron-Resendiz S., Schroeder R., Parsons L.H.et al. Functional consequences of repeated (+/-)3,4- methylenedioxymethamphetamine (MDMA) treatment in rhesus monkeys. Neuropsychopharmacology. 24:2001;230-239.
60. Taffe M.A., Davis S.D., Yuan J., Schroeder R., Hatzidimitriou G., Parsons L.H.et al. Cognitive performance of MDMA-treated rhesus monkeys: sensitivity to serotonergic challenge. Neuropsychopharmacology. 27:2002;993-1005.
61. Taffe M.A., Davis S.A., Gutierrez T., Gold L.H. Ketamine impairs multiple cognitive domains in rhesus monkeys. Drug Alcohol Depend. 68:2002;174-186.
62. Taffe M.A., Weed M.R., Gutierrez T., Davis S.A., Gold L.H. Differential muscarinic and NMDA contributions to visuo-spatial paired-associate learning in rhesus monkeys. Psychopharmacology. 160:2002;253-262.
63. Thompson G.C., Thompson A.M., Garrett K.M., Britton B.H. Serotonin and serotonin receptors in the central auditory system. Otolaryngol. Head Neck Surg. 110:1994;93-102.
64. Tohgi H., Abe T., Takahashi S., Kimura M., Takahashi J., Kikuchi T. Concentrations of serotonin and its related substances in the cerebrospinal fluid in patients with Alzheimer type dementia. Neurosci. Lett. 141:1992;9-12.
65. Tohgi H., Abe T., Takahashi S., Takahashi J., Hamato H. Concentrations of serotonin and its related substances in the cerebrospinal fluid of parkinsonian patients and their relations to the severity of symptoms. Neurosci. Lett. 150:1993;71-74.
66. van Praag H.M. Anxiety and increased aggression as pacemakers of depression. Acta Psychiatr. Scand., Suppl. 393:1998;81-88.
67. Vaughn D.M., Coleman E., Simpson S.T., Whitmer B., Satjawatcharaphong C. A rostrocaudal gradient for neurotransmitter metabolites and a caudorostral gradient for protein in canine cerebrospinal fluid. Am. J. Vet. Res. 49:1988;2134-2137.
68. Verkes R.J., Gijsman H.J., Pieters M.S., Schoemaker R.C., de Visser S., Kuijpers M.et al. Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology (Berl.). 153:2001;196-202.
69. Weed M.R., Gold L.H. The effects of dopaminergic agents on reaction time in rhesus monkeys. Psychopharmacology (Berl.). 137:1998;33-42.
70. Weed M.R., Taffe M.A., Polis I., Roberts A.C., Robbins T.W., Koob G.F.et al. Performance norms for a rhesus monkey neuropsychological testing battery: acquisition and long-term performance. Cogn. Brain Res. 8:1999;184-201.
71. Wester P., Bergstrom U., Eriksson A., Gezelius C., Hardy J., Winblad B. Ventricular cerebrospinal fluid monoamine transmitter and metabolite concentrations reflect human brain neurochemistry in autopsy cases. J. Neurochem. 54:1990;1148-1156.
72. Williams W.A., Shoaf S.E., Hommer D., Rawlings R., Linnoila M. Effects of acute tryptophan depletion on plasma and cerebrospinal fluid tryptophan and 5-hydroxyindoleacetic acid in normal volunteers. J. Neurochem. 72:1999;1641-1647.
73. Winsauer P.J., McCann U.D., Yuan J., Delatte M.S., Stevenson M.W., Ricaurte G.A.et al. Effects of fenfluramine, m-CPP and triazolam on repeated-acquisition in squirrel monkeys before and after neurotoxic MDMA administration. Psychopharmacology (Berl.). 159:2002;388-396.
74. Young S.N., Ervin F.R., Pihl R.O., Finn P. Biochemical aspects of tryptophan depletion in primates. Psychopharmacology (Berl.). 98:1989;508-511.
75. Zakzanis K.K., Young D.A. Memory impairment in abstinent MDMA ("ecstasy") users: a longitudinal investigation. Neurology. 56:2001;966-969.